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Abstract Transcription of genes for enzymes of the ornithine
cycle is activated by hormones such as glucocorticoids and
glucagon. Promoters and enhancers of several genes for the
enzymes interact with the CCAAT/enhancer-binding protein
(C/EBP) family of transcription factors, and C/EBPL has been
suggested to mediate glucocorticoid response of the gene for
arginase, the last enzyme of the cycle. To determine the
contribution of C/EBPL to hormonal regulation of genes for
ornithine cycle enzymes, we examined mice with targeted
disruption of the C/EBPL gene. Induction of genes for the
enzymes by intraperitoneal injection of dexamethasone and
glucagon was almost intact in the liver of C/EBPL-deficient mice.
On the other hand, in primary-cultured hepatocytes derived from
C/EBPL-deficient mice, induction of genes for the first enzyme
carbamylphosphate synthetase, as well as for arginase, in
response to dexamethasone and/or glucagon was severely
impaired. Therefore, C/EBPL is required for hormonal induction
of the genes for ornithine cycle enzymes in primary-cultured
hepatocytes, while the deficiency of C/EBPL is compensated for
in vivo. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The ornithine cycle in the liver is an enzyme system which
converts toxic ammonia derived from amino acids into urea.
The cycle consists of ¢ve enzymes, i.e. carbamylphosphate
synthetase (CPS), ornithine transcarbamylase (OTC), argini-
nosuccinate synthetase (AS), argininosuccinate lyase (AL),
and arginase. Genes for the enzymes are induced during peri-
natal period largely in a coordinated manner, and postnatally
are regulated in response to dietary changes (for review see
[1,2]). These regulations of the genes are mediated mainly by
three hormones: glucagon and glucocorticoids induce, while
insulin represses, the genes for ornithine cycle enzymes except
for OTC [1,2].
Induction of mRNAs for the enzymes by glucagon via the
cAMP pathway is known as the primary hormonal response,
since it follows a rapid time course without a lag time, and
since it does not require on-going protein synthesis [3]. A
transcription factor(s) that acts as the target of the cAMP
pathway and is responsible for the induction remains to be
identi¢ed. On the other hand, the induction by glucocorticoids
follows a delayed time course with a lag time of several hours
and is blocked by a protein synthesis inhibitor cycloheximide,
exhibiting the typical feature of the secondary hormonal re-
sponse that is mediated by a newly synthesized transcription
factor(s) [3].
The CCAAT/enhancer-binding protein (C/EBP) family is
the prototype family of basic region leucine zipper (bZIP)-
type transcription factors [4,5] (for review see [6]). We have
postulated that C/EBPL, a member of this family [7^12], me-
diates the secondary glucocorticoid response [13,14] : gluco-
corticoids stimulate transcription of the C/EBPL gene [13],
and newly synthesized C/EBPL in turn activates the arginase
gene through binding to the delayed glucocorticoid-responsive
element of the arginase enhancer [14]. It has been also sug-
gested that C/EBPL is involved in glucagon response, based
on the observations that the C/EBPL gene is induced by glu-
cagon/cAMP [13,15,16], and that C/EBPL is phosphorylated
by stimulation of the cAMP/protein kinase A pathway [17^
19].
Besides the arginase enhancer, C/EBP family members in-
teract with the promoter and enhancer regions of CPS [20,21],
the enhancer region of OTC [22,23], and the promoter region
of arginase [24,25]. Previously we showed that neonatal mice
lacking C/EBPK [26] su¡er from hyperammonemia associated
with impaired expression of the genes for ornithine cycle en-
zymes [27], demonstrating a pivotal role of C/EBPK in expres-
sion of the genes for ornithine cycle enzymes during perinatal
period. Here we examined whether disruption of the C/EBL
gene [28,29] a¡ects expression of genes for the enzymes. In
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Fig. 1. Basal mRNA (A) and protein (B) levels for the ornithine cycle enzymes in livers of C/EBPL-de¢cient mice. Total RNAs and tissue ex-
tracts were prepared from the livers of wild-type (+/+) and C/EBPL-de¢cient (3/3) mice fed on standard diet, and subjected to RNA blot (A)
and immunoblot (B) analysis, respectively, as described in Section 2. Positions of 28S and 18S rRNAs (A) and molecular weight markers (rain-
bow markers, Amersham) consisting of myosin (220 kDa), phosphorylase B (97 kDa), bovine serum albumin (66 kDa), ovalbumin (46 kDa)
and carbonic anhydrase (30 kDa) (B) are indicated.
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Fig. 2. Intactness of hormonal regulation of mRNA levels for ornithine cycle enzymes in livers of C/EBPL-de¢cient mice. Wild-type (+/+) and
C/EBPL-de¢cient (3/3) mice, which had been fed on protein-free diet to decrease basal mRNA levels for ornithine cycle enzymes, were treated
with a combination of dexamethasone and glucagon (Dex+Gl), or their vehicles (3) as described in Section 2. Total RNAs derived from the
livers of mice were subjected to RNA blot analysis. Representative chemiluminograms are shown on the left. Quanti¢ed results of the chemilu-
minograms are presented on the right. mRNA levels relative to the level (100%) for wild-type mice on standard diet (Fig. 1) were assessed for
three independent experiments, and are represented as the mean+S.E.M. Signi¢cant di¡erence was evaluated by Student’s t-test. **, P6 0.01
vs. other groups.
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primary-cultured hepatocytes of the C/EBPL-de¢cient mice,
induction of genes for CPS and arginase by dexamethasone
and/or glucagon was severely impaired, indicating that
C/EBPL is essential in hormonal response of the genes for
ornithine cycle enzymes in primary hepatocytes.
2. Materials and methods
2.1. Animals
Mice heterozygous for the disruption of the C/EBPL gene [28] were
mated, and genotypes of their o¡spring were determined by Southern
blotting as described [28].
2.2. Diet and hormone administration
Following a shift to feeding with protein-free diet (Clea Japan Inc.,
Tokyo, Japan) on day 1, mice were injected intraperitoneally with
dexamethasone (5 Wg/g of body weight) and glucagon (2 Wg/g of
body weight) twice at 21:00 on day 6 and at 9:00 on day 7, and
were killed at 13:00.
2.3. Primary culture of hepatocytes and treatment with hormones
Mice fed on standard diet (25% protein; Clea) were subjected to
isolation of parenchymal hepatocytes by in situ collagenase perfusion
as described [30,31] on day 1, and 3U106 hepatocytes were plated
onto collagen-coated plastic dishes (100 mm diameter; Corning Inc.,
Corning, NY, USA) with 10 ml of Dulbecco’s modi¢ed Eagle’s me-
dium containing 5% fetal calf serum and 100 Wg/ml of streptomycin.
The medium was changed 24 h after the plating. On day 3, cells were
treated with 1U1036 M dexamethasone, 3U1038 M glucagon, or a
combination of both hormones for 4 or 12 h.
2.4. RNA blot analysis
Total RNA was isolated from the liver or cultured hepatocytes
using the acid guanidinium thiocyanate-phenol-chloroform extraction
procedure [32]. RNA (2 Wg per lane) was electrophoresed in denatur-
ing formaldehyde-agarose (1%) gels. After visualizing 28S and 18S
rRNAs by ethidium bromide staining to check the integrity of RNA
samples and equal loading, the RNA was blotted onto nylon mem-
branes. Digoxigenin-labeled antisense RNA probes were synthesized
using a transcription kit (Roche Diagnostics, Tokyo, Japan), from
cDNAs for the following proteins: CPS at nucleotide positions
2799^3237 [33], OTC [34], AS at nucleotide positions 326^775 [35],
AL [36], arginase [37], C/EBPK [23], C/EBPL [23], metallothionein
(MT) [38], and tyrosine aminotransferase (TAT) [39]. Hybridization,
washing and chemiluminescent detection on X-ray ¢lms were done as
recommended by Roche Diagnostics. Densitometric quanti¢cation
was done using MacBas software (Fuji Photo Film Co., Tokyo,
Japan).
2.5. Immunoblot analysis
Mouse livers were homogenized in nine volumes of 20 mM potas-
sium HEPES bu¡er (pH 7.4) containing 0.5% Triton X-100, 1 mM
dithiothreitol, 50 WM antipain, 50 WM leupeptin, 50 WM chymostatin,
and 50 WM pepstatin. The homogenates were centrifuged at 25 000Ug
for 30 min at 4‡C, and the supernatants were used as tissue extracts.
The extracts (20 Wg of protein) were subjected to sodium dodecyl
sulfate (SDS)^polyacrylamide gel electrophoresis, and proteins were
electrotransferred to nitrocellulose membranes. Immunodetection was
performed using an ECL kit (Amersham Pharmacia Biotech, Tokyo,
Japan) and antibodies against CPS [40], OTC [41], AS [42], AL [42]
and arginase [43]. Rainbow markers (Amersham Pharmacia Biotech)
were employed as molecular weight standards.
3. Results
3.1. Expression of genes for ornithine cycle enzymes in the liver
of C/EBPL-de¢cient mice
We previously showed that expression of genes for orni-
thine cycle enzymes is impaired in the liver of C/EBPK-de¢-
cient mice [27]. Here we examined whether it is also the case
for C/EBPL-de¢cient mice. Livers of 10- to 16-week-old
C/EBPL3=3 mice fed on standard diet were subjected to
RNA blot and immunoblot analyses. As shown in Fig. 1,
mRNA and protein levels for ornithine cycle enzymes
were almost comparable between C/EBPL3=3 and control
C/EBPL= mice. Therefore, basal expression of the enzyme
genes is intact in C/EBPL-de¢cient mice.
Hepatic C/EBPL is induced by glucocorticoids and gluca-
gon [13], and is likely to be involved in induction of the
arginase gene, especially in response to glucocorticoids [14].
We investigated whether induction of the genes for ornithine
cycle enzymes by the hormones is impaired or not in C/EBPL-
de¢cient mice (Fig. 2). Prior to administration of the hor-
mones, mice were fed on protein-free diet for 5 days, to reduce
basal mRNA levels for the enzymes and to see stronger fold
induction by the hormones, as described previously [44]. Sub-
sequently, mice were injected with a combination of dexa-
methasone and glucagon intraperitoneally. As shown in
Fig. 2, mRNA levels for the ornithine cycle enzymes, except
for OTC, were raised by the hormones, and their extents were
similar between C/EBPL3=3 and C/EBPL= mice. Therefore,
hormonal induction of the genes for the enzymes is intact in
C/EBPL3=3 mice in vivo.
C/EBPL mRNA levels in C/EBPL= mice were increased in
response to the hormones (Fig. 2), concordant with our pre-
vious results obtained with primary-cultured rat hepatocytes
[13]. Interestingly, the hormonal treatment lowered C/EBPK
mRNA levels by 56% in C/EBPL= mice, but not in C/
EBPL3=3 mice. The escape from the hormonal repression of
the C/EBPK gene in C/EBPL3=3 mice might be a compensa-
tory change for lack of C/EBPL.
3.2. Impaired hormonal induction of mRNAs for CPS and
arginase in primary-cultured C/EBPL-de¢cient hepatocytes
To examine immediate e¡ects of hormones on hepato-
cytes, we isolated and cultured primary hepatocytes from
C/EBPL3=3 and wild-type mice. The hepatocytes were treated
with dexamethasone and/or glucagon for 4 or 12 h, and RNA
blot analysis was carried out (Fig. 3). In wild-type hepato-
cytes, mRNA levels for CPS were increased by each hormone
and further by their combination. In C/EBPL3=3 hepatocytes,
these increases were almost completely lost. OTC mRNA lev-
els showed no apparent change in response to the hormones in
both genotypes. Increases in mRNA levels for AS and AL
were apparent with a combination of the hormones in wild-
type hepatocytes, and seemed to be marginally impaired in
C
Fig. 3. Impairment of hormonal regulation of mRNA levels for ornithine cycle enzymes in primary-cultured hepatocytes of C/EBPL-de¢cient
mice. Hepatocytes derived from wild-type (+/+) and C/EBPL-de¢cient (3/3) mice were treated with 1U1036 M dexamethasone (Dex), 3U1038
M glucagon (Gl) or a combination of both hormones (Dex+Gl), or not treated (3), for 4 or 12 h. Total RNAs prepared from the hepatocytes
were subjected to RNA blot analysis. Representative chemiluminograms are shown on the left. Quanti¢ed results of the chemiluminograms are
presented on the right. mRNA levels are expressed as values relative to the level (100%) in the liver of wild-type mice on standard diet (Fig.
1), except MT mRNA for which the level in cultured hepatocytes without hormonal treatment is assigned the value of one because of £uctua-
tion of MT mRNA levels in the liver of alive mice. Data were assessed for at least three independent experiments, and are represented as the
mean+S.E.M. Signi¢cant di¡erence from wild-type (+/+) mice was determined by Student’s t-test: **, P6 0.01; *, P6 0.05
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C/EBPL3=3 cells. mRNA levels for arginase in wild-type he-
patocytes were increased moderately by each hormone, and
strongly by their combination. In C/EBPL3=3 hepatocytes,
these increases were severely impaired.
As positive controls for hormonal responses, expression of
genes for MT and TAT was examined (Fig. 3). Induction of
the MT genes by glucocorticoids [45,46] and induction of the
TAT gene by glucocorticoids [47,48] or glucagon/cAMP [49]
have been reported to be caused in a primary manner. mRNA
levels for MT were raised by dexamethasone to the same ex-
tent in C/EBPL3=3 and control hepatocytes. Induction of the
TAT gene by dexamethasone was signi¢cantly but only par-
tially impaired in C/EBPL3=3 hepatocytes compared to wild-
type cells. Glucagon induction of the TAT gene was also
marginally impaired in C/EBPL3=3 hepatocytes. Therefore,
while C/EBPL is required for full hormonal induction of the
TAT gene, basic signal transduction pathways for the hor-
mones are almost intact in C/EBPL3=3 mice. Taken together
with intactness of glucocorticoid induction of the MT genes,
these observations serve as controls for speci¢c impairment of
hormonal induction of the genes for ornithine cycle enzymes,
especially for CPS and arginase, in C/EBPL3=3 hepatocytes.
Increases in the C/EBPL mRNA levels by dexamethasone
and/or glucagon were apparent in wild-type hepatocytes (Fig.
3), concordant with in vivo results described above and our
previous results for rat hepatocytes [13]. No signi¢cant varia-
tion in mRNA levels for C/EBPK was observed by any hor-
monal treatment in wild-type as well as C/EBPL3=3 hepato-
cytes, showing no apparent compensatory change in
expression of the C/EBPK gene. The cause for discrepancy
in hormonal response of the C/EBPK gene between in vivo
and in cultured hepatocytes remains to be investigated.
4. Discussion
In this study, we demonstrated that increases in mRNA
levels for the ornithine cycle enzymes, especially for CPS
and arginase, in response to dexamethasone and/or glucagon
were severely impaired in primary-cultured hepatocytes de-
rived from C/EBPL3=3 mice. Most likely, C/EBPL is essential
for hormonal induction of the enzyme genes at transcription
levels. On the other hand, in vivo, the lack of C/EBPL seems
to be compensated for, since no apparent defect of the hor-
monal induction was detected in C/EBPL3=3 mice. A possible
mechanism for this compensation is that C/EBPK escapes
from hormonal downregulation and persists at su⁄cient levels
in the liver of C/EBPL-de¢cient mice. However, many in-
vestigations remain to be done to examine this hypothesis.
Molecular mechanisms for the hormonal repression of the
C/EBPK gene and for its impairment in C/EBPL-de¢ciency
also remain to be determined.
Contribution of C/EBPL to glucocorticoid response in both
primary and secondary manners has been suggested. The pri-
mary glucocorticoid response, which is triggered by the hor-
mone^nuclear receptor complex, sometimes requires coopera-
tion with other transcription factors. C/EBPL is such an
accessory factor involved in the glucocorticoid induction of
the gene for phosphoenolpyruvate carboxykinase (PEPCK)
[50]. The glucocorticoid receptor (GR) and C/EBPL also syn-
ergistically activate the K1-acid glycoprotein gene in acute-
phase response [51^53] presumably by direct protein^protein
interaction between these two factors [52] and by sharing a
coactivator [53]. Functional synergism between the GR and
C/EBPL in a manner that does not depend on direct protein^
protein interaction nor on DNA-binding of the receptor was
also reported [54]. As for the secondary glucocorticoid re-
sponse, expression of the C/EBPL gene itself is induced by
glucocorticoids in a primary manner [13], and newly synthe-
sized C/EBPL in turn activates target genes such as the argi-
nase gene [14]. Therefore, de¢ciency of C/EBPL potentially
can result in impairment of both primary and secondary glu-
cocorticoid responses.
Since induction of the arginase gene by glucocorticoids is
caused mainly in a secondary manner [3], impairment of the
induction in C/EBPL-de¢cient mice is attributable to lack of
newly synthesized C/EBPL. Glucocorticoid response of the
CPS gene was at ¢rst noted to be secondary, based on delayed
time course and sensitivity to an inhibitor of protein synthesis
[3]. On the other hand, recent studies [21] showed that the
glucocorticoid response unit of the CPS enhancer interacts
directly with the GR as well as C/EBP family members, sug-
gesting involvement of the GR also in a primary manner and
its modi¢cation by C/EBP family members. Their exact roles
in the primary and secondary glucocorticoid response remain
to be clari¢ed.
Complicated glucocorticoid regulation of the CPS gene re-
sembles that of the PEPCK gene. The promoter region of the
PEPCK gene also interacts with the GR and C/EBP family
members [50,55], while a report [56] described that glucocorti-
coid response of this gene is caused in a secondary manner.
Recently, it was brie£y noted that glucocorticoid induction of
the PEPCK gene was impaired in the liver of C/EBPL3=3
mice [57].
Glucocorticoid induction of the TAT gene [47,48] as well as
of the MT genes [45,46] is directly triggered by the GR/hor-
mone complex in a primary manner. In this study, dexameth-
asone induction of the TAT gene, but not of the MT genes,
was partially impaired in primary hepatocytes of C/EBPL3=3
mice. It has been reported that induction of the TAT gene by
the GR/hormone complex is synergistically stimulated by
HNF-3 family members [58,59], and potentially also by
C/EBP family members [59]. The partial impairment of glu-
cocorticoid induction of the TAT gene in C/EBPL3=3 mice
might have resulted from loss of this synergism with C/EBPL.
In the previous studies, contributions of C/EBPK and
C/EBPL to transcriptional regulation by glucagon/cAMP
were controversial. While mRNA and protein levels of
C/EBPL in the liver or cultured hepatocytes are upregulated
by glucagon/cAMP [13,15,16], those of C/EBPK have been
reported to be unchanged [13,16] or rather decreased [15].
In addition, C/EBPL, but not C/EBPK, has been shown to
be phosphorylated by stimulation of the cAMP/protein kinase
A pathway [17^19]. Based on these observations, it was specu-
lated that C/EBPL is involved in mediating the e¡ects of glu-
cagon/cAMP more profoundly than C/EBPK is. However, re-
cent studies with knockout mice [16] or antisense RNA
expressed in hepatoma cells [60] suggested that C/EBPK,
rather than C/EBPL, is required for cAMP induction of the
PEPCK gene, while C/EBPL may compensate for the lack of
C/EBPK when appropriately induced [16]. Since the present
study suggests that C/EBPL-de¢ciency might be compensated
for by C/EBPK when present at su⁄cient levels, it is tempting
to speculate that C/EBPK and C/EBPL are reciprocally com-
pensatory at least in part for their functions. Molecular mech-
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anisms for induction of the CPS and arginase genes by glu-
cagon/cAMP via C/EBPK and C/EBPK remain to be eluci-
dated. It would be interesting to examine if binding sites for
C/EBP family members in regulatory regions of genes for CPS
[20,21] and arginase [14,24,61] can mediate e¡ects of gluca-
gon/cAMP.
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